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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive aged women, with a prevalence of between 8% and 13% depending on the population studied and definitions used (1, 2) . PCOS is complex with reproductive, metabolic and psychological features (1, 2) . Clinical practice in the assessment and management of PCOS is inconsistent, with key evidence practice gaps, whilst women internationally have highlighted delayed diagnosis and dissatisfaction with care (3) (4) (5) . Current guidelines either are limited in breadth, do not follow rigorous best practice in development, have not involved consumers, or are outdated (6) (7) (8) (9) (10) , resulting in inconsistent guidance for clinicians and women alike. To address these identified gaps, here we summarize the development process and recommendations from the first international evidence-based guideline for the assessment and management of PCOS, bringing together extensive consumer engagement and international collaboration with leading societies and organizations, multidisciplinary experts, and primary care representatives. In this process, the guideline development groups unanimously supported the Rotterdam diagnostic criteria for adult women.
This comprehensive evidence-based guideline builds on prior high quality guidelines and culminates from a rigorous, Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant, evidence-based guideline development process. It provides a single source of international evidence-based recommendations to guide clinical practice with the opportunity for adaptation in relevant health systems. Together with an extensive translation program, the aim is to reduce worldwide variation in care and promote high quality service provision to improve health outcomes and quality of life in women with PCOS. The guidelines are supported by a multifaceted international translation program with codesigned resources to enhance the skills of health professionals and empower women with PCOS, with an integrated comprehensive evaluation program.
WHAT DOES THIS MEAN FOR ADOLESCENTS AND WOMEN WITH PCOS?
This guideline aims to optimize evidence-based, consistent care that meets the needs and improves the quality of life of women with PCOS. The guideline and translation program were developed with full consumer participation at all stages, targeting areas and outcomes of priority for women with PCOS. The aim is to support women and their health care providers to optimize diagnosis, assessment and management of PCOS. There is an emphasis on partnership in care and empowerment of women with PCOS. Personal characteristics, preferences, culture and values are considered. With effective translation, the guideline and health professional and consumer resources will address gaps and priorities identified by women with PCOS and will promote vital future research.
MATERIALS AND METHODS
Best practice evidence-based guideline development methods were applied and are detailed in the full guideline and the technical reports and outlined in Figure 1 and available at https://www.monash.edu/medicine/sphpm/mchri/pcos (11) . The process aligns with all elements of the AGREEII tool for quality guideline assessment (12) . This involved extensive evidence synthesis and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework covering evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength (13) . Evidence synthesis methods are outlined in the full guideline and followed best practice (12) (13) (14) (15) . Categories include evidence-based or consensus recommendations with accompanying clinical practice points ( Table 1) .
Terms include "should," "could," and "should not," are informed by the nature of the recommendation (evidence or consensus), the GRADE framework and quality of the evidence and are independent descriptors reflecting the judgement of the multidisciplinary guideline development group (GDG), including consumers. They refer to overall interpretation and practical application of the recommendation, balancing benefits and harms. "Should" is used where benefits of the recommendation exceed harms, and where the recommendation can be trusted to guide practice. "Could" is used where either the quality of evidence was limited or the available studies demonstrate little clear advantage of one approach over another, or the balance of benefits to harm was unclear. "Should not" is used where there is either a lack of appropriate evidence, or the harms may outweigh the benefits.
The GRADE of the recommendation is determined by the guideline development group based on comprehensive structured consideration of all elements of the GRADE framework (4), including desirable effects, undesirable effects, balance of effects, resource requirements and cost effectiveness, equity, acceptability and feasibility and includes: * Conditional recommendation against the option; ** Conditional recommendation for either the option or the comparison; *** Conditional recommendation for the option; **** Strong recommendation for the option.
Quality of the evidence is categorized according to: the number and design of studies addressing the outcome; judgments about the quality of the studies and/or synthesized evidence, such as risk of bias, inconsistency, indirectness, imprecision, and any other considerations that may influence the quality of the evidence; key statistical data; and classification of the importance of the outcomes ( Table 2 ). The quality of evidence reflects the extent of confidence in an estimate of the effect to support a particular recommendation (4) and was largely determined by the expert evidence synthesis team.
GRADE acknowledges that evidence quality is a continuum; any discrete categorization involves a degree of arbitrariness. Nevertheless, the advantages of simplicity, transparency, and clarity outweigh these limitations (4) .
RESULTS
The recommendation table (Table 3 ) applies the category, descriptive terms, GRADE of the recommendations and the quality of the evidence. The full guideline is available at https:// www.monash.edu/medicine/sphpm/mchri/pcos. The full version of the guideline outlines the clinical need for the question, the clinical question, the evidence summary, the recommendation and practice points and a summary of the justification developed by the GDGs using the GRADE framework, refined by extensive international peer review. The comprehensive evidence reviews, profiles and GRADE frameworks supporting each recommendation, can be found at https://www.monash.edu/medicine/sphpm/mchri/pcos in the Supplementary Technical Reports. The peer review feedback, administrative report on guideline development and disclosure of interest process and declarations can be found at https://www.monash.edu/medicine/sphpm/mchri/pcos. Here we present the clinical topic area recommendations and practice points ( Table 3 ). This summary, the full guideline and technical reports are supported by a comprehensive co-designed translation program to optimize dissemination and impact with resources freely available at https:// www.monash.edu/medicine/sphpm/mchri/pcos.
DISCUSSION
The International Guideline for the Assessment and Management of PCOS and the related translation program aims to provide clinicians with a quality, reliable source of international evidence-based recommendations to guide consistent clinical practice and to empower women with evidence-based information. All recommendations were formulated after an assessment of the best available evidence, multidisciplinary clinical expertise, consumer preferences and structured review by the five GDGs. Detailed methods for stakeholder engagement and guideline development can be found at https://www.monash.edu/medicine/ sphpm/mchri/pcos. The guideline provides 166 recommendations: evidence-based recommendations (EBR) = 31, clinical consensus recommendations (CCR) = 59, and clinical practice points (CPP) = 76. Overall evidence is of low to moderate quality, requiring significant research expansion in this neglected, yet common condition.
We endorse the Rotterdam PCOS Diagnostic Criteria in adults (two of oligo-or anovulation, clinical and/or biochemical hyperandrogenism, or polycystic ovaries on ultrasound), after exclusion of related disorders. Where both oligo-or anovulation and hyperandrogenism are present, ultrasound is not necessary for diagnosis. In adolescents, both oligo-anovulation and hyperandrogenism are required, with ultrasound not recommended for diagnosis. Ultrasound criteria are refined with advancing technology. Antimüllerian hormone levels are not yet adequate for diagnosis of PCOS. Insulin resistance is recognized as a key feature of PCOS, yet clinical measurement is not recommended at the current time. Once diagnosed, assessment and management includes reproductive, metabolic, and psychological features. Education, self-empowerment, multidisciplinary care, and lifestyle intervention for prevention or management of excess weight are prioritized. Depressive and anxiety symptoms should be screened, assessed, and managed and health professionals should be aware of other impacts on emotional wellbeing and quality of life. Combined oral contraceptive pills are first-line pharmacological management for menstrual irregularity and hyperandrogenism, with no specific formulation recommended and with low-dose preparations preferred. Metformin is recommended in addition or alone, primarily for management of metabolic features. Letrozole is first-line pharmacological infertility therapy; with clomiphene and metformin both having a role, alone and in combination. In women with PCOS and anovulatory infertility, gonadotrophins are second line. In the absence of an absolute indication for IVF, women with PCOS and anovulatory infertility could be offered IVF third line where other ovulation induction therapies have failed.
The combined effects of the provision of a single source of evidence-based recommendations and a comprehensive international translation and dissemination program will amplify the impact of the guideline and recommendations globally. It will support and build the capability of health professionals to deliver high-quality, evidence-based assessment and management of PCOS and will augment the health literacy and selfmanagement of PCOS health consumers. The guideline recommendations are protected under copyright, however the process for adaption of guideline recommendations to the regional context is available at https://www.monash.edu/medicine/sphpm/mchri/pcos. The guideline and translation program will contribute to early diagnosis and improved health outcomes, and promote best-practice PCOS models of care. The translation program will be inclusive of a range of outputs such as; the first evidence-based PCOS APP (AskPCOS), a rigorously developed question prompt list to optimize health professional engagement, health literacy enhancing tools, comprehensive PCOS-related health information; internationally accessible health professional accredited courses, webinars with international expert panels, and e-health information resources available at https://www.monash.edu/ medicine/sphpm/mchri/pcos. Most importantly, the guideline and translation of the guideline is expected to improve patient experiences through the provision of timely and accurate diagnosis, accessible evidence-based information and improved multi-disciplinary support. Ultimately, this initiative may serve as an exemplar for international collaborative engagement and healthcare impact. Key elements included extensive collaboration, broad stakeholder representation, including consumer partnership, distributive leadership, adequate funding, robust project management and governance, adherence to best practice and integrated comprehensive translation and evaluation. The Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Polycystic Ovary Syndrome and the members of this Centre who coordinated this international guideline effort
2.
Our partner organizations are:
• American Society for Reproductive Medicine (ASRM)
• European Society of Human Reproduction and Embry-ology (ESHRE)
3.
Our collaborating and engaged societies and consumer groups: Other relevant organizations are welcome to partner in guideline translation once approved.
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Category (see Table 1 for definition) **** ⊕⊕◯◯ CCR Direct free testosterone assays, such as radiometric or enzyme-linked assays, preferably should not be used in assessment of biochemical hyperandrogenism in PCOS, as they demonstrate poor sensitivity, accuracy and precision.
Recommendation

GRADE and Quality
SCREENING, DIAGNOSTIC ASSESSMENT, RISK ASSESSMENT, AND LIFE-STAGE Irregular cycles and ovulatory dysfunction
CPP
Reliable assessment of biochemical hyperandrogenism is not possible in women on hormonal contraception, due to effects on sex hormone-binding globulin and altered gonadotrophin-dependent androgen production.
-CPP Where assessment of biochemical hyperandrogenism is important in women on hormonal contraception, drug withdrawal is recommended for three months or longer before measurement, and contraception management with a non-hormonal alternative is needed during this time.
-CPP Assessment of biochemical hyperandrogenism is most useful in establishing the diagnosis of PCOS and/or phenotype where clinical signs of hyperandrogenism (in particular hirsutism) are unclear or absent.
-CPP Interpretation of androgen levels needs to be guided by the reference ranges of the laboratory used, acknowledging that ranges for different methods and laboratories vary widely. Normal values are ideally based on levels from a well phenotyped healthy control population or by cluster analysis of a large general population considering age and pubertal specific stages.
-Fertil Steril. Author manuscript; available in PMC 2020 January 02.
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Category (see Table 1 for definition)
Recommendation
GRADE and Quality
CPP Where androgen levels are markedly above laboratory reference ranges, other causes of biochemical hyperandrogenism need to be considered. History of symptom onset and progression is critical in assessing for neoplasia, however, some androgen-secreting neoplasms may only induce mild to moderate increases in biochemical hyperandrogenism. 
CPP
The prevalence of hirsutism is the same across ethnicities, yet the mFG cut-off scores for defining hirsutism and the severity of hirsutism varies by ethnicity. Category (see Table 1 for definition)
Recommendation
GRADE and Quality
• Reporting of endometrial thickness and appearance is preferred; 3-layer endometrial assessment may be useful to screen for endometrial pathology
• Other ovarian and uterine pathology, as well as ovarian cysts, corpus luteum, dominant follicles ≥ 10 mm CPP There is a need for training in careful and meticulous follicle counting per ovary, to improve reporting.
Anti-müllerian hormone (AMH)
EBR Serum AMH levels should not yet be used as an alternative for the detection of PCOM or as a single test for the diagnosis of PCOS.
*** ⊕⊕◯◯
CPP
There is emerging evidence that with improved standardization of assays and established cutoff levels or thresholds based on large scale validation in populations of different ages and ethnicities, AMH assays will be more accurate in the detection of PCOM.
- Category (see Table 1 for definition) Category (see Table 1 for definition) -
Ethnic variation
Recommendation
GRADE and Quality
Recommendation
GRADE and Quality
Depressive and anxiety symptoms, screening and treatment
CCR
Health professionals should be aware that in PCOS, there is a high prevalence of moderate to severe anxiety and depressive symptoms in adults; and a likely increased prevalence in adolescents.
**** CCR Anxiety and depressive symptoms should be routinely screened in all adolescents and women with PCOS at diagnosis. If the screen for these symptoms and/or other aspects of emotional wellbeing is positive, further assessment and/or referral for assessment and treatment should be completed by suitably qualified health professionals, informed by regional guidelines.
**** CCR If treatment is warranted, psychological therapy and/or pharmacological treatment should be offered in PCOS, informed by regional clinical practice guidelines.
**** CPP The optimal interval for anxiety and depressive symptom screening is not known. A pragmatic approach could include repeat screening using clinical judgment, considering risk factors, comorbidities and life events.
-CPP Assessment of anxiety and or depressive symptoms involves assessment of risk factors, symptoms and severity. Symptoms can be screened according to regional guidelines, or by using simple stepwise approaches (see full guideline for details).
-CPP Where pharmacological treatment for anxiety and depression is offered in PCOS, the following need consideration: • Caution is needed to avoid inappropriate treatment with antidepressants or anxiolytics. Where mental health disorders are clearly documented and persistent, or if suicidal symptoms are present, treatment of depression or anxiety need to be informed by clinical regional practice guidelines.
• Use of agents that exacerbate PCOS symptoms, including weight gain, need careful consideration.
-CPP Factors including obesity, infertility, and hirsutism need consideration along with use of hormonal medications in PCOS, as they may independently exacerbate depressive and anxiety symptoms and other aspects of emotional wellbeing. *** CPP Negative body image, can be screened according to regional guidelines or by using a stepped approach (see full guideline for details.
-
Eating disorders and disordered eating CCR
All health professionals and women should be aware of the increased prevalence of eating disorders and disordered eating associated with PCOS.
** CCR
If eating disorders and disordered eating are suspected, further assessment, referral and treatment, including psychological therapy, could be offered by appropriately trained health professionals, informed by regional guidelines or by using a stepped approach (see full guideline for details).
**
Information resources, models of care, cultural and linguistic considerations
Fertil Steril. Author manuscript; available in PMC 2020 January 02.
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Category (see Table 1 for definition) Category (see Table 1 for definition) -
Recommendation
GRADE and Quality
Recommendation
GRADE and Quality
CPP
In women with PCOS, there is no or limited evidence that any specific energy equivalent diet type is better than another, or that there is any differential response to weight management intervention, compared to women without PCOS. 
_
Obesity and weight assessment CCR
Health professionals and women should be aware that women with PCOS have a higher prevalence of weight gain and obesity, presenting significant concerns for women, impacting on health and emotional wellbeing, with a clear need for prevention.
CCR
All those with PCOS should be offered regular monitoring for weight changes and excess weight (see Cardiovascular Disease Risk).
**** Fertil Steril. Author manuscript; available in PMC 2020 January 02.
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Recommendation
GRADE and Quality
CPP
When assessing weight, related stigma, negative body image and/or low self-esteem need to be considered and assessment needs to be respectful and considerate. Beforehand, explanations on the purpose and how the information will be used and the opportunity for questions and preferences needs to be provided, permission sought and scales and tape measures adequate. Implications of results need to be explained and where this impacts on emotional wellbeing, support provided.
-CPP Prevention of weight gain, monitoring of weight and encouraging evidence-based and socio-culturally appropriate healthy lifestyle is important in PCOS, particularly from adolescence. _
Combined oral contraceptive pills in combination with metformin and/or anti-androgen pharmacological agents
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Category (see Table 1 for definition) 
Recommendation
GRADE and Quality
CPP
In combination with the COCP, metformin may be most beneficial in high metabolic risk groups including those with diabetes risk factors, impaired glucose tolerance, or high-risk ethnic groups.
EBR
In combination with the COCP, antiandrogens should only be considered in PCOS to treat hirsutism, after six months or more of COCP and cosmetic therapy have failed to adequately improve symptoms.
** ⊕⊕◯◯
CCR
In combination with the COCP, antiandrogens could be considered for the treatment of androgen-related alopecia in PCOS.
** CPP
In PCOS, antiandrogens must be used with effective contraception, to avoid male foetal undervirilisation. Variable availability and regulatory status of these agents is notable and for some agents, potential liver toxicity requires caution. Where metformin is prescribed the following need to be considered: • Adverse effects, including gastrointestinal side-effects that are generally dose dependent and self-limiting, need to be the subject of individualized discussion
• Starting at a low dose, with 500 mg increments 1-2 weekly and extended release preparations may minimize side effects
• Metformin use appears safe long-term, based on use in other populations, however ongoing requirement needs to be considered and use may be associated with low vitamin B12 levels
•
Use is generally off label and health professionals need to inform women and discuss the evidence, possible concerns and side effects.
Anti-obesity pharmacological agents
CCR Anti-obesity medications in addition to lifestyle, could be considered for the management of obesity in adults with PCOS after lifestyle intervention, as per general population recommendations.
-CPP For anti-obesity medications, cost, contraindications, side effects, variable availability and regulatory status need to be considered and pregnancy needs to be avoided whilst taking these medications. 
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Recommendation
GRADE and Quality
Inositol 
CPP
The use of ovulation induction agents, including letrozole, metformin and clomiphene citrate is off label in many countries. Where off label use of ovulation induction agents is allowed, health professionals need to inform women and discuss the evidence, possible concerns and side effects.
-CPP Pregnancy needs to be excluded prior to ovulation induction.
Unsuccessful, prolonged use of ovulation induction agents need to be avoided, due to poor success rates.
-Letrozole EBR Letrozole should be considered first line pharmacological treatment for ovulation induction in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation, pregnancy and live birth rates.
**** ⊕⊕◯◯ CPP Where letrozole is not available or use is not permitted or cost is prohibitive, health professionals can use other ovulation induction agents.
-CPP Health professionals and women need to be aware that the risk of multiple pregnancy appears to be less with letrozole, compared to clomiphene citrate.
Clomiphene citrate and metformin
EBR Clomiphene citrate could be used alone in women with PCOS with anovulatory infertility and no other infertility factors to improve ovulation and pregnancy rates. Table 1 for definition)
Recommendation
GRADE and Quality
• Periadnexal adhesion formation may be an associated risk.
Bariatric surgery CCR Bariatric surgery should be considered an experimental therapy in women with PCOS, for the purpose of having a healthy baby, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy.
* CPP
If bariatric surgery is to be prescribed, the following need to be considered:
• Comparative cost
•
The need for a structured weight management program involving diet, physical activity and interventions to improve psychological, musculoskeletal and cardiovascular health to continue post-operatively
• Perinatal risks such as small for gestational age, premature delivery, possibly increased infant mortality
• Potential benefits such as reduced incidence of large for gestational age fetus and gestational diabetes • Recommendations for pregnancy avoidance during periods of rapid weight loss and for at least 12 months after bariatric surgery with appropriate contraception.
-If pregnancy occurs, the following need to be considered:
• Awareness and preventative management of pre-and post-operative nutritional deficiencies is important, ideally in a specialist interdisciplinary care setting • Monitoring of fetal growth during pregnancy.
In vitro fertilization (IVF)
CCR
In the absence of an absolute indication for IVF ± intracytoplasmic sperm injection (ICSI), women with PCOS and anovulatory infertility could be offered IVF as third line therapy where first or second line ovulation induction therapies have failed.
***
CPP
In women with anovulatory PCOS, the use of IVF is effective and when elective single embryo transfer is used, multiple pregnancies can be minimized.
-CPP Women with PCOS undergoing IVF ± ICSI therapy need to be counselled prior to starting treatment including on: • Availability, cost and convenience • Increased risk of ovarian hyperstimulation syndrome • Options to reduce the risk of ovarian hyperstimulation.
-CCR Urinary or recombinant follicle stimulation hormone can be used in women with PCOS undergoing controlled ovarian hyperstimulation for IVF ± ICSI, with insufficient evidence to recommend specific follicle stimulating hormone (FSH) preparations.
-CCR Exogenous recombinant luteinizing hormone treatment should not be routinely used in combination with follicle stimulating hormone therapy in women with PCOS undergoing controlled ovarian hyperstimulation for IVF ± ICSI.
-EBR A gonadotrophin releasing hormone antagonist protocol is preferred in women with PCOS undergoing an IVF ± ICSI cycle, over a gonadotrophin releasing hormone agonist long protocol, to reduce the duration of stimulation, total gonadotrophin dose and incidence of ovarian hyperstimulation syndrome (OHSS).
*** ⊕⊕◯◯ CPP Human chorionic gonadotrophins is best used at the lowest doses to trigger final oocyte maturation in women with PCOS undergoing an IVF ± ICSI cycle to reduce the incidence of OHSS.
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Recommendation
GRADE and Quality
CPP
Triggering final oocyte maturation with a gonadotropin-releasing hormone (GnRH) agonist and freezing all suitable embryos could be considered in women with PCOS having an IVF/ICSI cycle with a GnRH antagonist protocol and at an increased risk of developing OHSS or where fresh embryo transfer is not planned.
In IVF ± ICSI cycles in women with PCOS, consideration needs to be given to an elective freeze of all embryos.
-EBR Adjunct metformin therapy could be used before and/or during follicle stimulating hormone ovarian stimulation in women with PCOS undergoing a IVF ± ICSI therapy with a GnRH agonist protocol, to improve the clinical pregnancy rate and reduce the risk of OHSS.
*** ⊕⊕◯◯
CCR
In a GnRH agonist protocol with adjunct metformin therapy, in women with PCOS undergoing IVF ± ICSI treatment, the following could be considered:
• Metformin commencement at the start of GnRH agonist treatment • Metformin use at a dose of between 1000 mg to 2550 mg daily • Metformin cessation at the time of the pregnancy test or menses (unless the metformin therapy is otherwise indicated)
• Metformin side-effects (see metformin section in this table) -CPP In IVF ± ICSI cycles, women with PCOS could be counselled on potential benefits of adjunct metformin in a GnRH antagonist protocol to reduce risk of ovarian hyperstimulation syndrome (see above for metformin therapy considerations).
CPP
The term in vitro maturation (IVM) treatment cycle is applied to "the maturation in vitro of immature cumulus oocyte complexes collected from antral follicles" (encompassing both stimulated and unstimulated cycles, but without the use of a human gonadotrophin trigger).
CCR
In units with sufficient expertise, IVM could be offered to achieve pregnancy and livebirth rates approaching those of standard IVF ± ICSI treatment without the risk of OHSS for women with PCOS, where an embryo is generated, then vitrified and thawed and transferred in a subsequent cycle. # Off-label prescribing occurs when a drug is prescribed for an indication, a route of administration, or a patient group that is not included in the approved product information document for that drug by the regulatory body. Prescribing off-label is often unavoidable and common and does not mean that the regulatory body has rejected the indication, but more commonly there has not been a submission to request evaluation of the indication or that patient group for any given drug.
